These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

389 related items for PubMed ID: 22340363

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study.
    Owens DR, Swallow R, Dugi KA, Woerle HJ.
    Diabet Med; 2011 Nov; 28(11):1352-61. PubMed ID: 21781152
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study.
    Gomis R, Espadero RM, Jones R, Woerle HJ, Dugi KA.
    Diabetes Obes Metab; 2011 Jul; 13(7):653-61. PubMed ID: 21410628
    [Abstract] [Full Text] [Related]

  • 4. Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study.
    Haak T, Meinicke T, Jones R, Weber S, von Eynatten M, Woerle HJ.
    Diabetes Obes Metab; 2012 Jun; 14(6):565-74. PubMed ID: 22356132
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Linagliptin provides effective, well-tolerated add-on therapy to pre-existing oral antidiabetic therapy over 1 year in Japanese patients with type 2 diabetes.
    Inagaki N, Watada H, Murai M, Kagimura T, Gong Y, Patel S, Woerle HJ.
    Diabetes Obes Metab; 2013 Sep; 15(9):833-43. PubMed ID: 23565760
    [Abstract] [Full Text] [Related]

  • 10. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.
    Taskinen MR, Rosenstock J, Tamminen I, Kubiak R, Patel S, Dugi KA, Woerle HJ.
    Diabetes Obes Metab; 2011 Jan; 13(1):65-74. PubMed ID: 21114605
    [Abstract] [Full Text] [Related]

  • 11. Comparison of dipeptidyl peptidase-4 inhibitors and pioglitazone combination therapy versus pioglitazone monotherapy in type 2 diabetes: A system review and meta-analysis.
    Wang B, Sun Y, Sang Y, Liu X, Liang J.
    Medicine (Baltimore); 2018 Nov; 97(46):e12633. PubMed ID: 30431561
    [Abstract] [Full Text] [Related]

  • 12. Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes.
    Wainstein J, Katz L, Engel SS, Xu L, Golm GT, Hussain S, O'Neill EA, Kaufman KD, Goldstein BJ.
    Diabetes Obes Metab; 2012 May; 14(5):409-18. PubMed ID: 22059736
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis.
    Wu D, Li L, Liu C.
    Diabetes Obes Metab; 2014 Jan; 16(1):30-7. PubMed ID: 23803146
    [Abstract] [Full Text] [Related]

  • 14. Linagliptin: a review of its use in the management of type 2 diabetes mellitus.
    Deeks ED.
    Drugs; 2012 Sep 10; 72(13):1793-824. PubMed ID: 22913735
    [Abstract] [Full Text] [Related]

  • 15. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial.
    Gallwitz B, Rosenstock J, Rauch T, Bhattacharya S, Patel S, von Eynatten M, Dugi KA, Woerle HJ.
    Lancet; 2012 Aug 04; 380(9840):475-83. PubMed ID: 22748821
    [Abstract] [Full Text] [Related]

  • 16. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin.
    DeFronzo RA, Lewin A, Patel S, Liu D, Kaste R, Woerle HJ, Broedl UC.
    Diabetes Care; 2015 Mar 04; 38(3):384-93. PubMed ID: 25583754
    [Abstract] [Full Text] [Related]

  • 17. [The efficacy and safety of linagliptin in elderly patients with type 2 diabetes: a pooled analysis of eight placebo-controlled clinical trials].
    Guo XH, Feng ZK, Xu LH.
    Zhonghua Nei Ke Za Zhi; 2017 Aug 01; 56(8):588-594. PubMed ID: 28789492
    [Abstract] [Full Text] [Related]

  • 18. Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study.
    Bosi E, Ellis GC, Wilson CA, Fleck PR.
    Diabetes Obes Metab; 2011 Dec 01; 13(12):1088-96. PubMed ID: 21733058
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial.
    Ross SA, Rafeiro E, Meinicke T, Toorawa R, Weber-Born S, Woerle HJ.
    Curr Med Res Opin; 2012 Sep 01; 28(9):1465-74. PubMed ID: 22816729
    [Abstract] [Full Text] [Related]

  • 20. A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea.
    Moses RG, Kalra S, Brook D, Sockler J, Monyak J, Visvanathan J, Montanaro M, Fisher SA.
    Diabetes Obes Metab; 2014 May 01; 16(5):443-50. PubMed ID: 24205943
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.